Pre-market and outsourced market access solutions as well as patient support services and HUB services ensure optimal access and clinical outcomes

BERWYN, Pennsylvania, January 11, 2022– (COMMERCIAL THREAD) –AscellaHealth, a global specialty pharmacy and healthcare solutions company, announces a full suite of Specialty Pharmacy (SP) services including pre-market, outsourced market access, wholesale, 3PL, Distribution of limited distribution drugs (LDD) and personalized patient assistance and HUB services. AscellaHealth now serves as an extension of the pharmaceutical company’s sales or market access team with outsourced market access solutions that provide strategic payer expertise, usage management, transfer programs and real-time data access.

AscellaHealth’s capabilities span the entire product lifecycle and prescribing process, streamlining communications between prescriber, patient, and pharmacy to remove barriers, reduce refill time, improve the patient journey, and optimize results.

“As a true industry partner with a deep understanding of payor composition and value, AscellaHealth’s outsourced market access solutions amplify the sales and market access team activities of the business. ‘a business,’ said Dea Belazi, President and CEO of AscellaHealth. “Our in-depth experience and expertise in payer reimbursement and strategy development, our in-depth understanding of the competitive environment, our programs designed to generate brand volume analytics and data-driven cost savings translate into through optimal patient access to products in the main specialty and rare disease categories. . “

The AscellaHealth service portfolio also includes personalized clinical support programs and interventions that lead to improved treatment adherence. As Belazi explains, “Our LDD pharmacy and our partners offer centers of excellence in many specialties and high touch capabilities to further improve the patient experience, reduce refill time and optimize results.”

AscellaHealth’s pre-market and market access solutions ensure products are successfully brought to market, removing barriers so patients can access treatment when they need it most. AscellaHealth’s LDD delivery model ensures that patients can seamlessly access medications and get the tactile support they need.

Belazi adds: “Our patient support begins when the prescriber submits a registration for their patient. From there, we coordinate the verification of the benefits, ensure the drug reaches the patient in a timely manner, and implement key interventions at key points in therapy. This includes the management of side effects. , with patient engagement initiatives throughout the process for optimal results. Our goal is to remove all possible obstacles to obtaining the best possible results for each specialty or patient with a rare disease. “

AscellaHealth’s comprehensive portfolio of services for the life sciences is customizable to meet client needs, available “à la carte” and includes:

  • Pre-marketing strategies

  • Outsourced market access solutions

  • Wholesale, distribution and 3PL services

  • LDD execution

  • Custom compliance and persistence programs

  • Simplified prior authorizations

  • Technology-based patient engagement

  • Copay and financial aid programs

  • Real-time Rx data and analysis

“Our full range of tailor-made services for pharmaceutical manufacturers is designed to optimize access to products, increase clinical outcomes and improve the quality of life of patients with specialized, rare or orphan diseases,” Belazi concludes. .

About AscellaHealth LLC
AscellaHealth is a global pharmacy and specialty healthcare services organization serving payers, providers, life sciences and patients, offering a comprehensive portfolio of personalized, technology-based specialty pharmacy and medical management services. . Winner Inc. 5000 2021, AscellaHealth’s unique, patient-centered approach relies on proprietary technological processes for innovative programs and services that optimize health outcomes and quality of life for patients with complex chronic diseases or rare diseases that require specialized drugs and / or genes and cell therapies. Visit

See the source version on


Nicole dufour
RCR communications
201.641.1911 x 54

Source link